Evolution of Plasmodium falciparum antimalarial drug resistance markers post-adoption of artemisinin-based combination therapies in Yaounde, Cameroon

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Evolution of Plasmodium falciparum antimalarial drug resistance markers post-adoption of artemisinin-based combination therapies in Yaounde, Cameroon. / Niba, Peter Thelma Ngwa; Nji, Akindeh Mbuh; Chedjou, Jean Paul Kengne; Hansson, Helle; Hocke, Emma Filtenborg; Ali, Innocent Mbulli; Achonduh-Atijegbe, Olivia; Evehe, Marie Solange B.; Jørgensen, Marie Helene Munck; Fomboh, Calvino Tah; Cui, Liwang; Stresman, Gillian; Bigoga, Jude D.; Alifrangis, Michael; Mbacham, Wilfred F.

In: International Journal of Infectious Diseases, Vol. 132, 2023, p. 108-117.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Niba, PTN, Nji, AM, Chedjou, JPK, Hansson, H, Hocke, EF, Ali, IM, Achonduh-Atijegbe, O, Evehe, MSB, Jørgensen, MHM, Fomboh, CT, Cui, L, Stresman, G, Bigoga, JD, Alifrangis, M & Mbacham, WF 2023, 'Evolution of Plasmodium falciparum antimalarial drug resistance markers post-adoption of artemisinin-based combination therapies in Yaounde, Cameroon', International Journal of Infectious Diseases, vol. 132, pp. 108-117. https://doi.org/10.1016/j.ijid.2023.03.050

APA

Niba, P. T. N., Nji, A. M., Chedjou, J. P. K., Hansson, H., Hocke, E. F., Ali, I. M., Achonduh-Atijegbe, O., Evehe, M. S. B., Jørgensen, M. H. M., Fomboh, C. T., Cui, L., Stresman, G., Bigoga, J. D., Alifrangis, M., & Mbacham, W. F. (2023). Evolution of Plasmodium falciparum antimalarial drug resistance markers post-adoption of artemisinin-based combination therapies in Yaounde, Cameroon. International Journal of Infectious Diseases, 132, 108-117. https://doi.org/10.1016/j.ijid.2023.03.050

Vancouver

Niba PTN, Nji AM, Chedjou JPK, Hansson H, Hocke EF, Ali IM et al. Evolution of Plasmodium falciparum antimalarial drug resistance markers post-adoption of artemisinin-based combination therapies in Yaounde, Cameroon. International Journal of Infectious Diseases. 2023;132:108-117. https://doi.org/10.1016/j.ijid.2023.03.050

Author

Niba, Peter Thelma Ngwa ; Nji, Akindeh Mbuh ; Chedjou, Jean Paul Kengne ; Hansson, Helle ; Hocke, Emma Filtenborg ; Ali, Innocent Mbulli ; Achonduh-Atijegbe, Olivia ; Evehe, Marie Solange B. ; Jørgensen, Marie Helene Munck ; Fomboh, Calvino Tah ; Cui, Liwang ; Stresman, Gillian ; Bigoga, Jude D. ; Alifrangis, Michael ; Mbacham, Wilfred F. / Evolution of Plasmodium falciparum antimalarial drug resistance markers post-adoption of artemisinin-based combination therapies in Yaounde, Cameroon. In: International Journal of Infectious Diseases. 2023 ; Vol. 132. pp. 108-117.

Bibtex

@article{98f777720fda4750ba6a49b30063945d,
title = "Evolution of Plasmodium falciparum antimalarial drug resistance markers post-adoption of artemisinin-based combination therapies in Yaounde, Cameroon",
abstract = "Objectives: This study aimed to investigate the evolution of Plasmodium falciparum antimalarial drug resistance markers by comparing the pre- and post-adoption of artemisinin-based combination therapies (ACTs) in Yaounde, Cameroon. Methods: The molecular characterization of known antimalarial drug resistance markers (Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, and Pfk13) in P. falciparum-positive samples collected in 2014 and 2019-2020 was achieved using nested polymerase chain reaction, followed by targeted amplicon deep sequencing on the Illumina MiSeq platform. Data derived were compared with those published during the pre-ACT adoption period from 2004 to 2006. Results: A high prevalence of Pfmdr1 184F, Pfdhfr 51I/59R/108N, and Pfdhps 437G mutant alleles was observed during the post-ACT adoption period. The Pfcrt 76T and Pfmdr1 86Y mutant alleles significantly declined between 2004 and 2020 (P <0.0001). Conversely, the resistance markers to antifolates, Pfdhfr 51I/59R/108N and Pfdhps 437G, significantly increased during the same study period (P <0.0001). We identified nine mutations in the propeller domains of Pfk13; although they were all present in single parasite isolates, none of them are known to confer artemisinin resistance. Conclusion: This study documented a near-complete reversion to sensitive parasites for markers conferring resistance to the 4-aminoquinolines and arylamino alcohols in Yaounde. In contrast, the Pfdhfr mutations associated with pyrimethamine resistance are moving toward saturation.",
keywords = "Artemisinin-based combination therapies, Cameroon, Drug resistance, Evolution, Plasmodium falciparum, Targeted amplicon deep sequencing",
author = "Niba, {Peter Thelma Ngwa} and Nji, {Akindeh Mbuh} and Chedjou, {Jean Paul Kengne} and Helle Hansson and Hocke, {Emma Filtenborg} and Ali, {Innocent Mbulli} and Olivia Achonduh-Atijegbe and Evehe, {Marie Solange B.} and J{\o}rgensen, {Marie Helene Munck} and Fomboh, {Calvino Tah} and Liwang Cui and Gillian Stresman and Bigoga, {Jude D.} and Michael Alifrangis and Mbacham, {Wilfred F.}",
note = "Publisher Copyright: {\textcopyright} 2023 The Authors",
year = "2023",
doi = "10.1016/j.ijid.2023.03.050",
language = "English",
volume = "132",
pages = "108--117",
journal = "International Journal of Infectious Diseases",
issn = "1201-9712",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Evolution of Plasmodium falciparum antimalarial drug resistance markers post-adoption of artemisinin-based combination therapies in Yaounde, Cameroon

AU - Niba, Peter Thelma Ngwa

AU - Nji, Akindeh Mbuh

AU - Chedjou, Jean Paul Kengne

AU - Hansson, Helle

AU - Hocke, Emma Filtenborg

AU - Ali, Innocent Mbulli

AU - Achonduh-Atijegbe, Olivia

AU - Evehe, Marie Solange B.

AU - Jørgensen, Marie Helene Munck

AU - Fomboh, Calvino Tah

AU - Cui, Liwang

AU - Stresman, Gillian

AU - Bigoga, Jude D.

AU - Alifrangis, Michael

AU - Mbacham, Wilfred F.

N1 - Publisher Copyright: © 2023 The Authors

PY - 2023

Y1 - 2023

N2 - Objectives: This study aimed to investigate the evolution of Plasmodium falciparum antimalarial drug resistance markers by comparing the pre- and post-adoption of artemisinin-based combination therapies (ACTs) in Yaounde, Cameroon. Methods: The molecular characterization of known antimalarial drug resistance markers (Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, and Pfk13) in P. falciparum-positive samples collected in 2014 and 2019-2020 was achieved using nested polymerase chain reaction, followed by targeted amplicon deep sequencing on the Illumina MiSeq platform. Data derived were compared with those published during the pre-ACT adoption period from 2004 to 2006. Results: A high prevalence of Pfmdr1 184F, Pfdhfr 51I/59R/108N, and Pfdhps 437G mutant alleles was observed during the post-ACT adoption period. The Pfcrt 76T and Pfmdr1 86Y mutant alleles significantly declined between 2004 and 2020 (P <0.0001). Conversely, the resistance markers to antifolates, Pfdhfr 51I/59R/108N and Pfdhps 437G, significantly increased during the same study period (P <0.0001). We identified nine mutations in the propeller domains of Pfk13; although they were all present in single parasite isolates, none of them are known to confer artemisinin resistance. Conclusion: This study documented a near-complete reversion to sensitive parasites for markers conferring resistance to the 4-aminoquinolines and arylamino alcohols in Yaounde. In contrast, the Pfdhfr mutations associated with pyrimethamine resistance are moving toward saturation.

AB - Objectives: This study aimed to investigate the evolution of Plasmodium falciparum antimalarial drug resistance markers by comparing the pre- and post-adoption of artemisinin-based combination therapies (ACTs) in Yaounde, Cameroon. Methods: The molecular characterization of known antimalarial drug resistance markers (Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, and Pfk13) in P. falciparum-positive samples collected in 2014 and 2019-2020 was achieved using nested polymerase chain reaction, followed by targeted amplicon deep sequencing on the Illumina MiSeq platform. Data derived were compared with those published during the pre-ACT adoption period from 2004 to 2006. Results: A high prevalence of Pfmdr1 184F, Pfdhfr 51I/59R/108N, and Pfdhps 437G mutant alleles was observed during the post-ACT adoption period. The Pfcrt 76T and Pfmdr1 86Y mutant alleles significantly declined between 2004 and 2020 (P <0.0001). Conversely, the resistance markers to antifolates, Pfdhfr 51I/59R/108N and Pfdhps 437G, significantly increased during the same study period (P <0.0001). We identified nine mutations in the propeller domains of Pfk13; although they were all present in single parasite isolates, none of them are known to confer artemisinin resistance. Conclusion: This study documented a near-complete reversion to sensitive parasites for markers conferring resistance to the 4-aminoquinolines and arylamino alcohols in Yaounde. In contrast, the Pfdhfr mutations associated with pyrimethamine resistance are moving toward saturation.

KW - Artemisinin-based combination therapies

KW - Cameroon

KW - Drug resistance

KW - Evolution

KW - Plasmodium falciparum

KW - Targeted amplicon deep sequencing

U2 - 10.1016/j.ijid.2023.03.050

DO - 10.1016/j.ijid.2023.03.050

M3 - Journal article

C2 - 37028468

AN - SCOPUS:85158005793

VL - 132

SP - 108

EP - 117

JO - International Journal of Infectious Diseases

JF - International Journal of Infectious Diseases

SN - 1201-9712

ER -

ID: 347297589